Predicting antidepressant response using artificial intelligence

Ai,Brain,Implant,Discovery,Concept,Collage,Art.,Young,Male,Person

Holly Fraser discusses new findings on whether and how we can predict antidepressant response using artificial intelligence.

[read the full story...]

Maintenance or discontinuation of antidepressants for depression? Findings from the ANTLER trial

For every 6 people stopping their medication there was one additional relapse compared to those who maintained their antidepressant treatment, suggesting that stopping medication has an increased risk of relapse.

Raphael Rifkin-Zybutz and Sameer Jauhar summarise the recently published ANTLER trial, which explores whether antidepressant maintenance can reduce the risk of relapse in depression.

[read the full story...]

Antidepressants for youth depression: Cochrane review confirms they should not be the first port of call

Pharmaceutical medicine pills, tablets and capsules on mint background. Top view. Flat lay. Copy space. Medicine concepts. Minimalistic abstract concept. Neo mint color

Susannah Murphy summarises a new Cochrane review and network meta-analysis, which provides the best evidence to date about new generation antidepressants for depression in children and adolescents.

[read the full story...]

In adults with major depression, antidepressants may increase the risk of suicide

shutterstock_409500925

Douglas Badenoch explores a meta-analysis of follow-up data from clinical trials of antidepressants, which found a small but significant increase in suicide risk.

[read the full story...]

SSRIs and suicidality: effects of SSRIs on rating-scale-assessed suicidality in adults with depression

sam-austin-266386-unsplash

Rina Dutta and Patrick McLaughlin summarise a new study looking at the effects of SSRIs (Selective Serotonin Reuptake Inhibitors) on rating-scale-assessed suicidality in adults with depression.

This study published in the British Journal of Psychiatry supports the conclusion that SSRIs remain a safe and effective treatment in depression for those aged 18 and over.

[read the full story...]

Depression in later life: who benefits most from antidepressants plus exercise?

walk-1385880_1280

Linda Gask explores an RCT of physical exercise for depression in later life, which considers the best way to customise the intervention for primary care.

[read the full story...]

Adding antidepressants to antipsychotics in schizophrenia: do they work, for what, and are they safe?

7687091514_3bffb55cb0_k

Alex Langford explores the emerging findings from a recent meta-analysis looking at the efficacy and safety of antidepressants added to antipsychotics for people with schizophrenia and schizophrenia-like psychosis.

[read the full story...]

Antidepressants: benefits and harms in children and adults

344574172_eaccb04842_o

Samei Huda discusses the findings of a recent review into suicidality and aggression during antidepressant treatment. The systematic review and meta-analyses were based on clinical study reports and included some important adverse effects of antidepressants in children and young people.

[read the full story...]

Pharmacotherapy for anxiety and comorbid alcohol use disorders

shutterstock_224941060

Natasha Clarke summarises a recent Cochrane review of pharmacotherapy for anxiety and comorbid alcohol use disorders, which found only very low quality evidence about the effectiveness of medication (buspirone, paroxetine, sertraline) for treating patients with both conditions.

[read the full story...]

CBT is more cost-effective than SSRI alone as treatment for panic disorder

shutterstock_32610631crop

In addition to its impact on quality of life, panic disorder can have a number of costly consequences such as lost productivity – particularly if also associated with agoraphobia. Cost-effectiveness is therefore an important consideration in choosing the optimal treatment for panic disorder, which might improve value via the cost side of the equation. A recent [read the full story…]